Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | GFER | P55789 | 2/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.36 |
| ▸ | HPN | P05981 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.36 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6156433 | 0.92 | F10 (0.43) | F10SMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL6157482 | 0.87 | F10 (0.68) | F10SMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL6157569 | 0.86 | TP53 (0.38) | F10SMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL6156353 | 0.84 | TP53 (0.40) | SMN1; SMN2MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL6156664 | 0.83 | TP53 (0.40) | F10SMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL5164572 | 0.83 | F10 (0.77) | F10SMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL6156656 | 0.83 | F10 (0.47) | F10SMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL5165637 | 0.80 | F10 (0.61) | F10SMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL5164794 | 0.79 | F10 (0.60) | F10SMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL6159517 | 0.79 | F10 (0.37) | F10SMN1; SMN2NPC1RAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171102-A1 | Semicarbazide derivatives for combating thromboembolic diseases | MERCK PATENT GMBH (DE) | 2005-08-04 | — | — | US | claimed |
| EP-1501814-A1 | SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES | MERCK PATENT GmbH (DE) | 2005-02-02 | — | — | EP | claimed |
| WO-2003093254-A1 | SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES | MERCK PATENT GMBH (DE) | 2003-11-13 | — | — | WO | claimed |
| US-20050171102-A1 | Semicarbazide derivatives for combating thromboembolic diseases | MERCK PATENT GMBH (DE) | 2005-08-04 | — | — | US | disclosed |
| EP-1501814-A1 | SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES | MERCK PATENT GmbH (DE) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093254-A1 | SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES | MERCK PATENT GMBH (DE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171102-A1 | Semicarbazide derivatives for combating thromboembolic diseases | SERPINC1, F11, F12 | F10 6/4885SMN1; SMN2 3250/4885NPC1 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.